3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Conditions
Squamous Intraepithelial Lesions
1
Papillomavirus Infections
1
Mucositis
1
Hematologic Neoplasms
1
HIV Infections
1
Gallbladder Neoplasms
1
Breast Carcinoma In Situ
1
Bile Duct Neoplasms
1
Anus Neoplasms
1
Acquired Immunodeficiency Syndrome
1
Interventions
Olanzapine
4
Cyclophosphamide
4
Voriconazole
3
Tranexamic Acid
3
Standard of Care
3
nilotinib
2
letermovir
2
fludarabine phosphate
2
Zoledronic Acid
2
Whole-Body Irradiation
2
Practice Guidelines as Topic
2
Peripheral Blood Stem Cell Transplantation
2
Mycophenolic Acid
2
Methods
2
Imatinib Mesylate
2
Educational Status
2
Early Intervention, Educational
2
Doxorubicin
2
Cyclosporins
2
Cyclosporine
2
venetoclax
1
trihexyltetradecylphosphonium chloride
1
thymoglobulin
1
shengxuening
1
posaconazole
1
pembrolizumab
1
olaparib
1
maribavir
1
lenvatinib
1
ferrous succinate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Hematologic Neoplasms
×
Laser Therapy
×
Clear all
NCT02696408
2020-01-29
STOP MUCITES
Institut de Cancérologie de la Loire
Phase 3
Completed
234 enrolled